Absci Q2 2026: Cash Runway Extended to H2 2028, ABS-201 Data Readouts on Track
ABSI has more than doubled off its 52-week low of $2.24.
Summary
Absci's Q2 2026 financials show a cash runway now extending into the second half of 2028, alongside updated timelines for its lead drug candidate ABS-201.
Key Events · Earnings and Guidance · ABSI
-
Cash Runway Extended to H2 2028
Cash and equivalents of $201.1 million, bolstered by a $93.6 million public offering and $12.5 million in ATM sales, fund operations past key clinical data readouts.
-
ABS-201 Clinical Timelines Reaffirmed
Interim proof-of-concept data for ABS-201 in pattern hair loss expected H2 2026, full data early 2027; Phase 2 trial in endometriosis planned for Q4 2026 with data in H2 2027.
-
June 2026 Public Offering Details
13.5 million shares sold at $7.41 per share, raising $93.6 million net; Eli Lilly participated, signaling strategic confidence.
-
ATM Program Provides Additional Flexibility
$12.5 million raised via ATM in H1 2026; $84 million remains available under the $100 million program.
Analysis · ABSI · Industrial Applications And Services
The standout in Absci's Q2 2026 report is a fortified balance sheet that pushes the cash runway into the second half of 2028, well past the expected proof-of-concept data for lead asset ABS-201. A net loss of $33.2 million on minimal revenue was offset by a June 2026 public offering and ATM sales, lifting cash to $201.1 million. With funding secured, the company confirmed that interim Phase 1 data for ABS-201 in pattern hair loss is expected in H2 2026, full data in early 2027, and a Phase 2 trial in endometriosis is planned for Q4 2026. These milestones are now fully covered, reducing near-term dilution risk. The offering priced at $7.41—a discount to today's $8.02—but Eli Lilly's participation signals strategic validation. The report also details the ATM program, with $84 million remaining, providing additional flexibility. While the operating loss widened year-over-year, the increased R&D spend is directed at advancing the clinical pipeline, which is the core value driver.
At the time of this filing, ABSI was trading at $8.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $2.24 to $12.06. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.